KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Amortization (2018 - 2023)

Historic Amortization for BioNTech SE (BNTX) over the last 6 years, with Q2 2023 value amounting to $21.7 billion.

  • BioNTech SE's Amortization rose 2069.88% to $21.7 billion in Q2 2023 from the same period last year, while for Jun 2023 it was $79.9 billion, marking a year-over-year increase of 7245.22%. This contributed to the annual value of $200659.7 for FY2019, which is 25195.2% up from last year.
  • Per BioNTech SE's latest filing, its Amortization stood at $21.7 billion for Q2 2023, which was up 2069.88% from $21.8 billion recorded in Q1 2023.
  • BioNTech SE's Amortization's 5-year high stood at $21.8 billion during Q1 2023, with a 5-year trough of -$133.7 million in Q4 2019.
  • In the last 5 years, BioNTech SE's Amortization had a median value of $245.3 million in 2020 and averaged $8.3 billion.
  • Its Amortization has fluctuated over the past 5 years, first tumbled by 15057.05% in 2019, then surged by 408750.67% in 2021.
  • Over the past 5 years, BioNTech SE's Amortization (Quarter) stood at -$133.7 million in 2019, then surged by 283.52% to $245.3 million in 2020, then soared by 4087.51% to $10.3 billion in 2021, then skyrocketed by 80.26% to $18.5 billion in 2022, then grew by 17.06% to $21.7 billion in 2023.
  • Its Amortization stands at $21.7 billion for Q2 2023, versus $21.8 billion for Q1 2023 and $18.5 billion for Q3 2022.